CoChat

The innate immune sensor Toll-like receptor 2 controls the senescence-associated secretory phenotype

Open access

Published version of a preprint

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Abstract

Innate immune sensing is essential for the proinflammatory program in cellular senescence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciadv.aaw0254

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 TLR2 expression is induced during OIS. (A) Schematic showing IMR90 ER:RAS cells treated with 4OHT undergo OIS. IMR90 ER:STOP cells serve as a control and retain proliferative capacity with 4OHT. (B) Quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis of TLR family member expression in IMR90 ER:RAS and ER:STOP cells treated with 4OHT for 5 and 8 days. (C) Western blot of TLR2 expression in IMR90 ER:RAS and ER:STOP (ER:S) cells with up to 10 days of 4OHT treatment (top). The 5-bromo-2′-deoxyuridine (BrdU) incorporation in IMR90 ER:RAS cells treated with 4OHT for up to 8 days, as indicated. (D) RNA was extracted from snap-frozen liver samples from wild-type (WT) mice 6 days following hydrodynamic delivery of NrasG12V/D38A (n = 5) and NrasG12V (n = 4) transposons. tlr2 mRNA expression was measured using qRT-PCR. Scatter plots represents value per animal, with the horizontal line representing group means ± SEM. Statistical significance was calculated using Students two-tailed t test. **P < 0.01. (E) Immunohistochemical staining for Nras and Tlr2 in consecutive liver sections from corresponding mice in (D) showing that oncogenic NrasG12V expressing, but not NrasG12V/D38A expressing, hepatocytes express Tlr2. Scale bars, 50 μm.
Fig. 1 TLR2 expression is induced during OIS. (A) Schematic showing IMR90 ER:RAS cells treated with 4OHT undergo OIS. IMR90 ER:STOP cells serve as a control and retain proliferative capacity with 4OHT. (B) Quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis of TLR family member expression in IMR90 ER:RAS and ER:STOP cells treated with 4OHT for 5 and 8 days. (C) Western blot of TLR2 expression in IMR90 ER:RAS and ER:STOP (ER:S) cells with up to 10 days of 4OHT treatment (top). The 5-bromo-2′-deoxyuridine (BrdU) incorporation in IMR90 ER:RAS cells treated with 4OHT for up to 8 days, as indicated. (D) RNA was extracted from snap-frozen liver samples from wild-type (WT) mice 6 days following hydrodynamic delivery of NrasG12V/D38A (n = 5) and NrasG12V (n = 4) transposons. tlr2 mRNA expression was measured using qRT-PCR. Scatter plots represents value per animal, with the horizontal line representing group means ± SEM. Statistical significance was calculated using Students two-tailed t test. **P < 0.01. (E) Immunohistochemical staining for Nras and Tlr2 in consecutive liver sections from corresponding mice in (D) showing that oncogenic NrasG12V expressing, but not NrasG12V/D38A expressing, hepatocytes express Tlr2. Scale bars, 50 μm.CC BY · PubMed Central
Fig. 2 TLR2 and TLR10 regulate the SASP in OIS. (A) Immunofluorescence staining and high-content analysis for IL-1β expression in IMR90 ER:RAS cells treated with 4OHT for 8 days and repeatedly transfected with pooled siRNA targeting TLR1, TLR2, TLR6, and TLR10. Nontarget (NT)-pooled siRNA was used as control. Representative images are shown. Scale bars, 250 μm. DAPI, 4′,6-diamidino-2-phenylindole. (B) Western blot analysis against indicated antibodies in IMR90 ER:RAS cells treated with 4OHT for 8 days and repeatedly transfected with pooled and individual siRNA targeting TLR2 and TLR10. T2-P, siRNA TLR2 pool; T2-4, individual TLR2 siRNA; T10-P, siRNA TLR10 pool; T10-2, individual TLR10 siRNA. Nontarget pooled siRNA was used as control. Western blot against β-actin is shown as a loading control. (C) SASP factor regulation by qRT-PCR in ER:RAS cells treated with 4OHT for 8 days and repeatedly transfected with pooled siRNA targeting TLR2 and TLR10. Results are expressed as means ± SEM of three independent experiments. (D) Venn diagram showing the number of genes that are significantly induced by TLR2 and TLR10 during OIS in the transcriptome analysis (AmpliSeq) in IMR90 ER:RAS cells treated with 4OHT and transfected with pooled siRNA targeting TLR2 and TLR10 for 8 days (GSE127116). The intersection represents the number of genes regulated by both TLR2 and TLR10. This signature of 267 genes will be used for GSEA in additional senescence transcriptomes in Fig. 4 and figs. S4 and S7. (E) Top regulated terms identified through of coregulated genes in (H) using DAVID gene ontology analysis. Chart bars represent Benjamin-adjusted P value of term enrichment. (F) Heat map of SASP factor expression obtained from the transcriptome analysis (AmpliSeq) in IMR90 ER:RAS cells following siRNA knockdown of TLR2 and TLR10 for 8 days of 4OHT treatment. (G) GSEA enrichment plot of RELA signature in TLR2 siRNA-transfected IMR90 ER:RAS 4OHT-induced cells. (H) IMR90 ER:RAS cells were transfected with indicated siRNA for 8 days with 4OHT. Western blot for phosphorylation and total levels of IKKa/β and p38 mitogen-activated protein kinase (MAPK) was performed. (I) IMR90 ER:RAS cells were treated with 4OHT and repeatedly transfected with indicated pooled siRNA and nontarget siRNA as control for 5 days. Western blots were conducted for phosphorylation of p65 and total p65 protein levels. All statistical significance was calculated using one-way analysis of variance (ANOVA). ***P < 0.001, **P < 0.01, and *P < 0.05. ns, not significant.
Fig. 2 TLR2 and TLR10 regulate the SASP in OIS. (A) Immunofluorescence staining and high-content analysis for IL-1β expression in IMR90 ER:RAS cells treated with 4OHT for 8 days and repeatedly transfected with pooled siRNA targeting TLR1, TLR2, TLR6, and TLR10. Nontarget (NT)-pooled siRNA was used as control. Representative images are shown. Scale bars, 250 μm. DAPI, 4′,6-diamidino-2-phenylindole. (B) Western blot analysis against indicated antibodies in IMR90 ER:RAS cells treated with 4OHT for 8 days and repeatedly transfected with pooled and individual siRNA targeting TLR2 and TLR10. T2-P, siRNA TLR2 pool; T2-4, individual TLR2 siRNA; T10-P, siRNA TLR10 pool; T10-2, individual TLR10 siRNA. Nontarget pooled siRNA was used as control. Western blot against β-actin is shown as a loading control. (C) SASP factor regulation by qRT-PCR in ER:RAS cells treated with 4OHT for 8 days and repeatedly transfected with pooled siRNA targeting TLR2 and TLR10. Results are expressed as means ± SEM of three independent experiments. (D) Venn diagram showing the number of genes that are significantly induced by TLR2 and TLR10 during OIS in the transcriptome analysis (AmpliSeq) in IMR90 ER:RAS cells treated with 4OHT and transfected with pooled siRNA targeting TLR2 and TLR10 for 8 days (GSE127116). The intersection represents the number of genes regulated by both TLR2 and TLR10. This signature of 267 genes will be used for GSEA in additional senescence transcriptomes in Fig. 4 and figs. S4 and S7. (E) Top regulated terms identified through of coregulated genes in (H) using DAVID gene ontology analysis. Chart bars represent Benjamin-adjusted P value of term enrichment. (F) Heat map of SASP factor expression obtained from the transcriptome analysis (AmpliSeq) in IMR90 ER:RAS cells following siRNA knockdown of TLR2 and TLR10 for 8 days of 4OHT treatment. (G) GSEA enrichment plot of RELA signature in TLR2 siRNA-transfected IMR90 ER:RAS 4OHT-induced cells. (H) IMR90 ER:RAS cells were transfected with indicated siRNA for 8 days with 4OHT. Western blot for phosphorylation and total levels of IKKa/β and p38 mitogen-activated protein kinase (MAPK) was performed. (I) IMR90 ER:RAS cells were treated with 4OHT and repeatedly transfected with indicated pooled siRNA and nontarget siRNA as control for 5 days. Western blots were conducted for phosphorylation of p65 and total p65 protein levels. All statistical significance was calculated using one-way analysis of variance (ANOVA). ***P < 0.001, **P < 0.01, and *P < 0.05. ns, not significant.CC BY · PubMed Central
Fig. 3 TLR2 reinforces the cell cycle arrest in OIS. (A) IMR90 cells infected with TLR2 or H-RasG12V expression vectors or empty vector (EV) control were seeded at low density and stained with crystal violet after 2 weeks. The staining was quantified to obtain relative cell content. Results are expressed as means ± SEM of three independent experiments. (B) SA-β-Gal staining was carried out on TLR2- and H-RasG12V–expressing cells. Results are expressed as means (% positive cells) ± SEM of three independent experiments. (C to G) IMR90 ER:RAS cells were treated with 4OHT and repeatedly transfected with indicated siRNA and pooled nontarget siRNA control. siTP53 was used as a positive control. (C) After 5 days of treatment, a BrdU incorporation assay was conducted. Results are expressed as means ± SEM of three independent experiments. (D) Total DAPI-stained nuclei counted by high-content analysis at 8 days. Results are expressed as means ± SEM of three independent experiments. (E) After 10 days, SA-β-Gal activity assay was conducted. Scale bars, 100 μm. (F) qRT-PCR analysis of CDKN1A, CDKN2A, and CDKN2B transcripts. Results are expressed as means ± SEM of three independent experiments. (G) Western blot for p53 expression at 8 days. All statistical significance was calculated using one-way analysis of variance (ANOVA). ***P < 0.001, **P < 0.01, and *P < 0.05.
Fig. 3 TLR2 reinforces the cell cycle arrest in OIS. (A) IMR90 cells infected with TLR2 or H-RasG12V expression vectors or empty vector (EV) control were seeded at low density and stained with crystal violet after 2 weeks. The staining was quantified to obtain relative cell content. Results are expressed as means ± SEM of three independent experiments. (B) SA-β-Gal staining was carried out on TLR2- and H-RasG12V–expressing cells. Results are expressed as means (% positive cells) ± SEM of three independent experiments. (C to G) IMR90 ER:RAS cells were treated with 4OHT and repeatedly transfected with indicated siRNA and pooled nontarget siRNA control. siTP53 was used as a positive control. (C) After 5 days of treatment, a BrdU incorporation assay was conducted. Results are expressed as means ± SEM of three independent experiments. (D) Total DAPI-stained nuclei counted by high-content analysis at 8 days. Results are expressed as means ± SEM of three independent experiments. (E) After 10 days, SA-β-Gal activity assay was conducted. Scale bars, 100 μm. (F) qRT-PCR analysis of CDKN1A, CDKN2A, and CDKN2B transcripts. Results are expressed as means ± SEM of three independent experiments. (G) Western blot for p53 expression at 8 days. All statistical significance was calculated using one-way analysis of variance (ANOVA). ***P < 0.001, **P < 0.01, and *P < 0.05.CC BY · PubMed Central
Fig. 4 A-SAA signaling through TLR2 controls the SASP. (A) Heat map showing the relative fold change of acute-phase response transcripts of samples from the acute-phase response gene set from the mRNA transcriptomes. Transcriptome analysis (AmpliSeq) was performed in mRNA from IMR90 ER:RAS cells transfected with pooled siRNA for TLR2 and TLR10 and nontarget pool as a control. Genes with significant changes between nontarget siRNA control and both TLR2 and TLR10 knockdown are in bold characters. Adjusted P values were calculated using Benjamini and Hochberg false discovery rate of three independent experiments. Bold genes represent adjusted P < 0.05. (B) qRT-PCR validation of acute-phase response targets from samples obtained similarly to (A). Results are expressed as means ± SEM of three independent experiments. Statistical significance was calculated using one-way ANOVA and Dunnett’s multiple comparisons tests. ***P < 0.001, **P < 0.01, and *P < 0.05. (C) qRT-PCR analysis of A-SAA expression in IMR90 ER:RAS and ER:STOP cells with up to 10 days of 4OHT treatment. (D) IMR90 ER:RAS cells were treated with 4OHT and repeatedly transfected with pooled siRNA targeting SAA1 and SAA2 and nontarget siRNA as control for 8 days. Western blot of the conditioned medium for indicated antibodies. (E) IMR90 cells transfected with pooled siRNA for TLR2 and TLR10 were treated with A-SAA (10 μg/ml) for 3 hours, and qRT-PCR was performed to measure IL1β expression. Results are expressed as means ± SEM of three independent experiments. (F) Immunofluorescence staining and quantification of IL-1β expression by high-content analysis. Scale bars, 250 μm. (G) qRT-PCR for IL1α, IL1β, IL6, and IL8 expression. Results are expressed as means ± SEM of three independent experiments. (H) IMR90 ER:RAS cells were transfected with siSAA2 and treated with 1 μm Pam2CSK4 for 5 days. qRT-PCR of IL1α, IL1β, and IL6 expression. (I) Heat map showing TLR2 SAA1 and SAA2 expression in available transcriptomic data from adriamycin (ADR) mediated therapy-induced senescence (TIS) lymphoma cells (GSE31099), OIS mediated by mutant BRAF in human melanocytes (OIS) (GSE46801), stasis in human mammary epithelial cells (HMEC) (GSE16058), DNA damage-induced senescence in BJ cells (DDR) (GSE13330), replicative senescence in BJ cells (replicative) (GSE13330), and developmental senescence in the mesonephros (developmental) (GSE49108). (J) GSEA plots for the 267 genes regulated coregulated by TLR2 and TLR10 in OIS (fig. S2H) in the transcriptomes from (I). All statistical significance was calculated using one-way ANOVA. ***P < 0.001, **P < 0.01, and *P < 0.05.
Fig. 4 A-SAA signaling through TLR2 controls the SASP. (A) Heat map showing the relative fold change of acute-phase response transcripts of samples from the acute-phase response gene set from the mRNA transcriptomes. Transcriptome analysis (AmpliSeq) was performed in mRNA from IMR90 ER:RAS cells transfected with pooled siRNA for TLR2 and TLR10 and nontarget pool as a control. Genes with significant changes between nontarget siRNA control and both TLR2 and TLR10 knockdown are in bold characters. Adjusted P values were calculated using Benjamini and Hochberg false discovery rate of three independent experiments. Bold genes represent adjusted P < 0.05. (B) qRT-PCR validation of acute-phase response targets from samples obtained similarly to (A). Results are expressed as means ± SEM of three independent experiments. Statistical significance was calculated using one-way ANOVA and Dunnett’s multiple comparisons tests. ***P < 0.001, **P < 0.01, and *P < 0.05. (C) qRT-PCR analysis of A-SAA expression in IMR90 ER:RAS and ER:STOP cells with up to 10 days of 4OHT treatment. (D) IMR90 ER:RAS cells were treated with 4OHT and repeatedly transfected with pooled siRNA targeting SAA1 and SAA2 and nontarget siRNA as control for 8 days. Western blot of the conditioned medium for indicated antibodies. (E) IMR90 cells transfected with pooled siRNA for TLR2 and TLR10 were treated with A-SAA (10 μg/ml) for 3 hours, and qRT-PCR was performed to measure IL1β expression. Results are expressed as means ± SEM of three independent experiments. (F) Immunofluorescence staining and quantification of IL-1β expression by high-content analysis. Scale bars, 250 μm. (G) qRT-PCR for IL1α, IL1β, IL6, and IL8 expression. Results are expressed as means ± SEM of three independent experiments. (H) IMR90 ER:RAS cells were transfected with siSAA2 and treated with 1 μm Pam2CSK4 for 5 days. qRT-PCR of IL1α, IL1β, and IL6 expression. (I) Heat map showing TLR2 SAA1 and SAA2 expression in available transcriptomic data from adriamycin (ADR) mediated therapy-induced senescence (TIS) lymphoma cells (GSE31099), OIS mediated by mutant BRAF in human melanocytes (OIS) (GSE46801), stasis in human mammary epithelial cells (HMEC) (GSE16058), DNA damage-induced senescence in BJ cells (DDR) (GSE13330), replicative senescence in BJ cells (replicative) (GSE13330), and developmental senescence in the mesonephros (developmental) (GSE49108). (J) GSEA plots for the 267 genes regulated coregulated by TLR2 and TLR10 in OIS (fig. S2H) in the transcriptomes from (I). All statistical significance was calculated using one-way ANOVA. ***P < 0.001, **P < 0.01, and *P < 0.05.CC BY · PubMed Central
Fig. 5 A-SAA and TLR2 expression is dependent on STING activation. (A and B) IMR90 ER:RAS cells were treated with 4OHT and repeatedly transfected with indicated pooled siRNA and nontarget siRNA as control for 8 days. TLR2, SAA1, and SAA2 transcripts were measured by qRT-PCR. Results are expressed as means ± SEM of three independent experiments. (C) IMR90 cells were transfected with siRNA targeting RELA, IRF3, TLR2, and STING for 2 days, followed by transfection with 2.5 μg of herrings-testes DNA (HT-DNA) for 24 hours. TLR2 transcripts were measured by qRT-PCR. Results are expressed as means ± SEM of three independent experiments. (D) Western blot for STING dimerization. HT-DNA transfection of IMR90 cells were used as positive control for STING dimerization. IMR90 ER:RAS cells were transfected with siRNA targeting TLR2, TLR10, and STING for 8 days with 4OHT. All statistical significance was calculated using a one-way ANOVA. ***P < 0.001, **P < 0.01, and *P < 0.05.
Fig. 5 A-SAA and TLR2 expression is dependent on STING activation. (A and B) IMR90 ER:RAS cells were treated with 4OHT and repeatedly transfected with indicated pooled siRNA and nontarget siRNA as control for 8 days. TLR2, SAA1, and SAA2 transcripts were measured by qRT-PCR. Results are expressed as means ± SEM of three independent experiments. (C) IMR90 cells were transfected with siRNA targeting RELA, IRF3, TLR2, and STING for 2 days, followed by transfection with 2.5 μg of herrings-testes DNA (HT-DNA) for 24 hours. TLR2 transcripts were measured by qRT-PCR. Results are expressed as means ± SEM of three independent experiments. (D) Western blot for STING dimerization. HT-DNA transfection of IMR90 cells were used as positive control for STING dimerization. IMR90 ER:RAS cells were transfected with siRNA targeting TLR2, TLR10, and STING for 8 days with 4OHT. All statistical significance was calculated using a one-way ANOVA. ***P < 0.001, **P < 0.01, and *P < 0.05.CC BY · PubMed Central
Fig. 6 tlr2 is necessary for SASP activation in vivo. (A) Representative IHC staining and IHC score quantification of IL-1α in PanIN generated in tlr2+/+ or tlr2−/− Pdx-Cre KrasG12D mice. Scatter plot represents the value for individual animals (dots), and the horizontal line represents group means (n = 5) ± SEM. Statistical significance was calculated using one-tailed Student’s t test. *P < 0.05 (B) qRT-PCR results for SASP factors IL-1β, IL-1α, and IL-6 from liver samples from WT and tlr2−/− mice 6 days after receiving hydrodynamic delivery of NrasG12V/D38A negative control or oncogenic NrasG12V transposon as indicated. Scatter plot represents the value for individual animals (dots), and the horizontal line represents group means (n = 3) ± SEM. Statistical significance was calculated using two-tailed students t test. *P < 0.05 and **P < 0.01. (C) Representative IHC staining for Nras, Tlr2, IL-1β, p21, and Biotin-SBB in corresponding liver sections from mice in (B). Scale bars, 50 μm.
Fig. 6 tlr2 is necessary for SASP activation in vivo. (A) Representative IHC staining and IHC score quantification of IL-1α in PanIN generated in tlr2+/+ or tlr2−/− Pdx-Cre KrasG12D mice. Scatter plot represents the value for individual animals (dots), and the horizontal line represents group means (n = 5) ± SEM. Statistical significance was calculated using one-tailed Student’s t test. *P < 0.05 (B) qRT-PCR results for SASP factors IL-1β, IL-1α, and IL-6 from liver samples from WT and tlr2−/− mice 6 days after receiving hydrodynamic delivery of NrasG12V/D38A negative control or oncogenic NrasG12V transposon as indicated. Scatter plot represents the value for individual animals (dots), and the horizontal line represents group means (n = 3) ± SEM. Statistical significance was calculated using two-tailed students t test. *P < 0.05 and **P < 0.01. (C) Representative IHC staining for Nras, Tlr2, IL-1β, p21, and Biotin-SBB in corresponding liver sections from mice in (B). Scale bars, 50 μm.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. 10.1016/j.cell.2008.06.049 · doi:10.1016/j.cell.2008.06.049 · Paper page

Cited by

See all 154

Metadata

Authors
Hari, P., Millar, F. R., Tarrats, N., Birch, J., Quintanilla, A., Rink, C. J., Fernández-Duran, I., Muir, M., Finch, A. J., Brunton, V. G., Passos, J. F., Morton, J. P., Boulter, L., & Acosta, J. C.
Affiliations
  • Edinburgh Cancer Research (GB)
  • Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK.
  • Newcastle University (GB)
  • Cancer Research UK Scotland Institute (GB)
  • Mayo Clinic (US)
  • Institute of Genetics and Cancer (GB)
Corresponding author
Acosta, Juan Carlos
Venue
Science Advances
Published
2019-06
Volume
5
Issue
6
Pages
eaaw0254-eaaw0254
ISSN
2375-2548 (ISSN-L)
OpenAlex
W2952061841
Cited by
154
References
55
Citations by year
2026: 20 · 2025: 15 · 2024: 23 · 2023: 21 · 2022: 21 · 2021: 36 · 2020: 16 · 2019: 2
FWCI
12.86
Type
journal article
Language
en
Open access
Locations
  • Science Advances (publishedVersion)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by-nc)
  • Queen Mary Research Online (Queen Mary University of London) (submittedVersion, cc-by)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by)
Funders
  • Wellcome Trust (203913/Z/16/Z)
  • College of Medicine and Veterinary Medicine, University of Edinburgh (R42576 MRC)
  • Biotechnology and Biological Sciences Research Council (BB/K017314/1)
  • Cancer Research UK (C47559/A16243, A20409, A25142)
  • University of Edinburgh chancellors fellowship (R42576 MRC)
  • Wellcome Trust ISSF
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
Keywords
TLR2, senescence-associated secretory phenotype, cellular senescence, serum amyloid A1, SAA2, damage-associated molecular patterns, innate immune recognition, cGAS-STING pathway, cytosolic DNA sensing, cell cycle arrest
MeSH terms
Alarmins, STING Protein, Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase, Serum Amyloid A Protein, Animals, Fibroblasts, Humans, Immunity, Innate, Membrane Proteins, Mice, Inbred C57BL, Nucleotidyltransferases, Tamoxifen, Signal Transduction, NF-kappa B, Cellular Senescence, Mice, Knockout, ras Proteins, RNA Interference, RNA, Small Interfering, p38 Mitogen-Activated Protein Kinases, Toll-Like Receptor 2, Toll-Like Receptor 10, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.